ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$17.80 USD
+0.42 (2.42%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $17.92 +0.12 (0.67%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
ARS Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SPRY 17.80 +0.42(2.42%)
Will SPRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
Other News for SPRY
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial ...
ARS Pharmaceuticals Inc (SPRY) Announces Upcoming Conference Call for Q2 2025 Financial Results ...
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
SPRY Gains Approval for Allergic Reaction Treatment in the UK | SPRY Stock News